论文部分内容阅读
目的观察康艾注射液联合大剂量维生素B6防治卡培他滨化疗所致手足综合征的效果。方法 38例肿瘤患者采用卡培他滨联合化疗,预防治疗组于化疗前3天给予口服维生素B6300mg/d,联合康艾注射液静脉滴注至化疗结束;对照组仅给予口服维生素B6300mg/d。结果预防治疗组手足综合征发生率为31.58%,且反应轻,无IV度者;对照组手足综合征发生率为57.89%,其中III度者26.32%。预防组手足综合征发生率明显低于对照组,差异有统计学意义(P<0.05),且程度轻。结论康艾注射液联合大剂量维生素B6预防卡培他滨所至手足综合征疗效确定,是较理想的预防治疗方案。
Objective To observe the effect of Kangai injection combined with high-dose vitamin B6 on prevention and treatment of hand-foot syndrome caused by capecitabine chemotherapy. Methods 38 cases of cancer patients were treated with capecitabine combined with chemotherapy, prophylactic treatment group given oral vitamin B6300mg / d 3 days before chemotherapy, combined Kangai injection intravenous infusion to the end of chemotherapy; the control group was given oral vitamin B6300mg / d. Results The incidence of hand-foot syndrome was 31.58% in the prevention and treatment group, with mild reaction and no IV degree. The incidence of hand-foot syndrome in the control group was 57.89%, of which, the III degree was 26.32%. The incidence of hand-foot syndrome was significantly lower in the prevention group than in the control group, with a significant difference (P <0.05). Conclusions Kangai injection combined with high-dose vitamin B6 to prevent hand-foot syndrome induced by capecitabine is an ideal preventive treatment.